Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (NCT04494425)
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Who can join: Review the eligibility criteria below.
Location: Research Site — Scottsdale, Arizona
Age range: 18 Years to 105 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (293 Sites)
Showing the first 25 of 293 sites.
- Research Site — Scottsdale, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
- Research Site — Los Angeles, California
- Research Site — Aurora, Colorado
- Research Site — Lakewood, Colorado
- Research Site — Washington D.C., District of Columbia
- Research Site — Jacksonville, Florida
- Research Site — Kansas City, Kansas
- Research Site — Louisville, Kentucky
- Research Site — Bethesda, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Detroit, Michigan
- Research Site — Rochester, Minnesota
- Research Site — St Louis, Missouri
- Research Site — Summit, New Jersey
- Research Site — Westbury, New York
- Research Site — Columbus, Ohio
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Nashville, Tennessee
- Research Site — Austin, Texas
- Research Site — Dallas, Texas
- Research Site — Houston, Texas
- Research Site — Houston, Texas
- Research Site — Norfolk, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Breast Cancer
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment — Irvine, California
- A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer — Nashville, Tennessee
Explore by condition: All Advanced or Metastatic Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.